How to build a tumor: An industry perspective.

Autor: Schueler J; Charles River Discovery Research Services Germany GmbH, Freiburg, Germany. Electronic address: julia.schueler@crl.com., Borenstein J; Bioengineering Division, Draper, Cambridge, MA, USA., Buti L; Charles River Discovery, Leiden, the Netherlands., Dong M; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany., Masmoudi F; Charles River Discovery, Leiden, the Netherlands., Hribar K; Cypre, South San Francisco, CA, USA., Anderson E; Charles River, Saffron Walden, UK., Sommergruber W; University of Applied Sciences, Department of Biotechnology, Vienna, Austria.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2022 Oct; Vol. 27 (10), pp. 103329. Date of Electronic Publication: 2022 Jul 28.
DOI: 10.1016/j.drudis.2022.07.014
Abstrakt: During the past 15 years, a plethora of innovative 3D in vitro systems has been developed. They offer the possibility of identifying crucial cellular and molecular contributors to the disease by permitting manipulation of each in isolation. However, improvements are needed particularly with respect to the predictivity and validity of those models. The major challenge now is to identify which assay and readout combination(s) best suits the current scientific question(s). A deep understanding of the different platforms along with their pros and cons is a prerequisite to make this decision. This review aims to give an overview of the most prominent systems with a focus on applications, translational relevance and adoption drivers from an industry perspective.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: